Brief: Adamis Pharmaceuticals Provides Enrollment Update Of Subjects In Phase 2/3 Study Of Tempol For The Treatment Of COVID-19

DMK Pharmaceuticals

07/02/2022 14:20

Feb 7 (Reuters) - Adamis Pharmaceuticals Corp  ADMP.O :
    * ADAMIS PHARMACEUTICALS PROVIDES ENROLLMENT UPDATE OF
SUBJECTS IN
PHASE 2/3 STUDY OF TEMPOL FOR THE TREATMENT OF COVID-19
    * ADAMIS PHARMACEUTICALS CORP - DATA SAFETY MONITORING BOARD
(DSMB) WILL NOW EXAMINE CLINICAL AND SAFETY DATA FROM FIRST 50
SUBJECTS

Source text for Eikon:  ID:nGNXbzWQC4 
Further company coverage:  ADMP.O 

 ((Reuters.Briefs@thomsonreuters.com;))